UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 243

Sortiert nach

The Role of Immunotherapy in Pancreatic Cancer

Current oncology (Toronto), 2022-09, Vol.29 (10), p.6864-6892

2022

Link zum Volltext

Verfügbarkeit prüfen

The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways

Cancers, 2022-05, Vol.14 (11), p.2619

2022

Link zum Volltext

Verfügbarkeit prüfen

The current state of molecular profiling in gastrointestinal malignancies

Biology direct, 2022-06, Vol.17 (1), p.15-15, Article 15

2022

Link zum Volltext

Verfügbarkeit prüfen

Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and COP1 in Metastasis

Cancers, 2023-03, Vol.15 (6), p.1831

2023

Link zum Volltext

Verfügbarkeit prüfen

Gastric carcinoma's primary presentation as multiple cutaneous nodules throughout the body

Cancer treatment and research communications, 2022, Vol.31, p.100532-100532, Article 100532

2022

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

Cancer medicine (Malden, MA), 2022-11, Vol.11 (22), p.4169-4181

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma

Advances in radiation oncology, 2016-01, Vol.1 (1), p.35-42

2016

Link zum Volltext

Verfügbarkeit prüfen

Anti-Ro60 Antibodies Utility as a Diagnostic Indicator of Pancreatic Cancer: A Case Report

Pancreas, 2022-11, Vol.51 (10), p.e121

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

Clinical cancer research, 2020-03, Vol.26 (6), p.1247-1257

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical cancer research, 2021-12, Vol.27 (23), p.6314-6322

2021

Link zum Volltext

Verfügbarkeit prüfen

MEK inhibitors in non-V600 BRAF mutations and fusions

Oncotarget, 2020-11, Vol.11 (44), p.3900-3903

2020

Link zum Volltext

Verfügbarkeit prüfen

Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review

Journal of thoracic disease, 2023-06, Vol.15 (6), p.3466-3487

2023

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer

Investigational new drugs, 2020-04, Vol.38 (2), p.392-401

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC)

International journal of radiation oncology, biology, physics, 2024-02, Vol.118 (2), p.362-367

2024

Link zum Volltext

Verfügbarkeit prüfen

Novel agents in mantle cell lymphoma

Best practice & research. Clinical haematology, 2012-06, Vol.25 (2), p.191-200

2012

Link zum Volltext

Verfügbarkeit prüfen

Biologics in bowel cancer

Journal of gastrointestinal oncology, 2017-06, Vol.8 (3), p.449-456

Noel, Marcus S

2017

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer

Journal of gastrointestinal cancer, 2024-06, Vol.55 (2), p.852-861

2024

Link zum Volltext

Verfügbarkeit prüfen

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

EClinicalMedicine, 2023-04, Vol.58, p.101897-101897, Article 101897

2023

Link zum Volltext

Verfügbarkeit prüfen

Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability

Journal of clinical oncology, 2013-01, Vol.31 (3), p.e37-e39

2013

Link zum Volltext

Verfügbarkeit prüfen

New and emerging treatment options for biliary tract cancer

OncoTargets and therapy, 2013-01, Vol.6 (default), p.1545-1552

2013

Link zum Volltext

Verfügbarkeit prüfen

Advances in adjuvant therapy of colon Cancer

Seminars in colon and rectal surgery, 2016-12, Vol.27 (4), p.204-212

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB192-LB192

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 243

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(223)
Mit Volltextzugriff
(224)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(136)
Life Sciences & Biomedicine
(111)
Humans
(89)
Male
(31)
Female
(29)
Oncology
(28)
Middle Aged
(21)
Adult
(20)
Aged
(20)
Animals
(18)
Life Sciences
(15)
Technology
(14)
Cancer
(13)
Patients
(13)
Science & Technology - Other Topics
(13)
General & Internal Medicine
(12)
Mice
(12)
Tumors
(12)
Aged, 80 And Over
(11)
Multidisciplinary Sciences
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The Role of Immunotherapy in Pancreatic Cancer

The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways

The current state of molecular profiling in gastrointestinal malignancies

Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and COP1 in Metastasis

Gastric carcinoma's primary presentation as multiple cutaneous nodules throughout the body

A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma

Anti-Ro60 Antibodies Utility as a Diagnostic Indicator of Pancreatic Cancer: A Case Report

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

MEK inhibitors in non-V600 BRAF mutations and fusions

Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review

A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer

Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC)

Novel agents in mantle cell lymphoma

Biologics in bowel cancer

Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability

New and emerging treatment options for biliary tract cancer

Advances in adjuvant therapy of colon Cancer

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and ICOP1/I in Metastasis

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialResearch in context

Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade

Suchergebnisse filtern